

# Marapharm Ventures Inc. CSE: MDM

FSE: 2MO

Unit #12 - 7621 Vantage Way, Delta British Columbia V4G 1A6 Telephone: 604-952-6676 Facsimile: 604-952-0988

LK2805201504

## NEWS RELEASE

### Company to Commence Trading Today on Frankfurt Stock Exchange

**May 28, 2015 – Vancouver BC.** – Les Kjosness, President & CEO, is pleased to announce Marapharm Ventures Inc. (the 'Company') is continuing to move forward in several areas and will begin trading on the Frankfurt Stock Exchange today under the symbol FSE: 2MO on Thursday May 28, 2015.

Marapharm intends to create a global entity by pursuing commercial ventures in the medical marijuana business. We were established to enter the emerging market created by Canada's new Marijuana for Medical Purposes Regulations ("MMPR"). The Company's original project is the construction of brand new facilities on 11 acres in British Columbia's Okanagan Valley with expansion plans in place to meet strategic advantages for growth and market penetration. Marapharm is currently in the process of its application for an MMPR license.

In May 2015, we announced the purchase of 5.9 acres in the Apex Industrial Park, located in North Las Vegas, Nevada. The Company has a provisional grow licence in place and will build a 70,000 square foot medical marijuana facility. Building plans are completed and are in the final rounds for permitting. Construction will start within 60 days.

In addition to the Las Vegas acquisition, Marapharm has entered into an LOI (letter of intent) with the same business corporation for a 90-day exclusive negotiation rights and the right of first refusal for two additional Nevada Medical Marijuana licences, one Medical and recreational Marijuana grow operation in Colorado, one grow operation and a medical dispensary licence in Washington State and one medical dispensary licence in California.

The Canadian market potential for medical marijuana is currently estimated at Cdn. \$1.2 billion and the world market potential is estimated at Cdn. \$115 billion. As a result, Marapharm is well positioned to enjoy significant and consistent revenue growth for many years.

On behalf of the Board  
"Les Kjosness"

President & CEO

For further information: Les Kjosness: 604-952-6676 [Les@Marapharm.com](mailto:Les@Marapharm.com)

Bayside Management Corp. Terry Yuck: 403-861-5775 [Terry@marapharm.com](mailto:Terry@marapharm.com)

The CSE has neither approved nor disapproved the accuracy of this news release.

This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectations. Important factors – including the availability of funds, the results of financing efforts, the results of exploration activities – that could cause actual results to differ materially from the Company's expectations are disclosed in the Companies' documents filed from time to time on SEDAR (see [www.sedar.com](http://www.sedar.com)). Readers are cautioned not to place undue reliance on these forward – looking statements, which speak only as of the date of this news release. The Company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward – looking statements, whether as a result of new information, future events or otherwise.